Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:
Research & Development India Leadership

Epidemic Expert Kang On Tackling nCoV And Science As A Leveler

  • Interviews

Executive Summary

Gagandeep Kang of the Translational Health Science and Technology Institute and Coalition for Epidemic Preparedness Innovations talks to Scrip about early efforts to tackle nCoV-2019 and shares glimpses into her life journey in a wide-ranging interview.

You may also be interested in...



Codagenix-Serum Join Fray To Develop SARS-CoV-2 Vaccine

Codagenix, a company backed by Novartis, Merck and the Bill & Melinda Gates Foundation, has tied up with India’s Serum Institute to develop a vaccine against SARS-CoV-2, joining a heated race against the dreaded COVID-19 outbreak.

Coronavirus: Can Companies Achieve Vaccine Ambition?

First Cetuximab Biosimilar Debuts In India; Merck KGaA Sticks To Guns

Alkem’s ‘affordable’ cetuximab biosimilar set to take on Erbitux in India, even as Merck KGaA pursues a court case seeking information and data related to efficacy and interchangeability of the Indian company's product.

Table

View full table

Topics

Related Companies

Tags:
Research & Development India Leadership
Latest Headlines

China Roundup: Rare Disease Approvals, Local mRNA Shots, CEO Visits

ASCO 2023 – Trop2 Could Validate Merck’s Savvy Deal With Kelun

Quick Listen: Scrip's Five Must-Know Things

ASCO 2023 – Deep And Early Responses Lift Hopes At Effector

See All
UsernamePublicRestriction

Register

SC141572

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By